Propeller Health Raises Strategic Investment from McKesson Ventures

MADISON, Wis., June 11, 2018 /PRNewswire/ -- Propeller Health, a leading digital therapeutics company, announced a strategic investment of an undisclosed amount from McKesson Ventures, adding to the $20M funding round announced last week.

Proceeds from the investment will provide further support for Propeller's development of additional connected medicines for the treatment of chronic respiratory disease, such as injectables for severe asthma, and expansion into new therapeutic areas, which may include immunology, diabetes, migraine and other diseases with high unmet medical need.

Propeller Health

"We've accumulated the expertise, infrastructure and distribution network to put connected medicines in the hands of people around the world," said David Van Sickle, co-founder and CEO of Propeller Health. "This strategic investment accelerates those efforts and provides opportunities to explore potential partnership models that can increase access to new digital medicines and positively impact more lives."

The Propeller platform enables leading medical technology and pharmaceutical companies to conceptualize, develop and commercialize digital medicines. Propeller also offers distribution at scale through its network of leading payers, pharmacies and PBMs such as Express Scripts.

"Propeller's strong base of clinical evidence demonstrates meaningful benefits to patients and all key stakeholders involved in delivering patient care. We are excited for their continued success as part of the 'digital supply chain,' an emerging category that will be integral to the future of medicine," said Carrie Hurwitz Williams, Principal of McKesson Ventures. "McKesson Ventures is uniquely positioned to help accelerate growth in the digital supply chain as our healthcare system becomes increasingly connected via secure data exchange and the use of digital therapies continues to rise."

Propeller recently announced a strategic partnership with Aptar Pharma to collaborate on the development of digital medicines for multiple therapeutic areas and diseases.

In addition to supporting better self-management and clinical care and treatment, Propeller is working with industry experts and regulators to advance clinical research, real-world evidence and the design and validation of novel endpoints.

Propeller's platform is backed by 8 FDA 510(k) clearances and CE marking, and the company continues to expand its global operations, now spanning 16 countries. Propeller's respiratory products have demonstrated significant increases in medication adherenceand health outcomes while delivering reductions in healthcare utilization, such as emergency room visits and hospitalizations.

About Propeller HealthPropeller Health is a leading digital therapeutics company dedicated to the development and commercialization of measurably better medicines. Propeller creates products to more effectively treat disease and improve clinical outcomes for patients across a range of therapeutic areas through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the US, Europe and Asia. For more information, visit www.propellerhealth.com.

About McKesson VenturesMcKesson Ventures is the venture capital arm of McKesson Corporation specializing in early and growth stage companies. McKesson Ventures targets companies that both catalyze and benefit from the key changes taking place in the U.S. health care landscape. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a health care services and information technology company dedicated to making the business of healthcare run better. We work with payers, hospitals, physician offices, pharmacies, pharmaceutical companies, and others across the spectrum of care to build healthier organizations that help deliver better care to patients in every setting. Visit www.mckessonventures.com to learn more.